CRO / CMO / CDMO

Delve into the world of CRO / CMO / CDMO in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on CRO / CMO / CDMO to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran
CompanyDeals

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran

Merck KGaA (ETR: MRK) announced that it has entered into a definitive agreement to acquire Silence Therapeutics plc (NASDAQ: SLN), a UK‑headquartered global clinical‑stage biotechnology company pioneering siRNA therapies in…

AbbVie's Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn's Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

AbbVie’s Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn’s Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Policy / RegulatoryR&D

Shenzhen Unveils Measures to Boost Biomedical and Medical Device Industries

Company

WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs

CompanyDeals

Frontier Biotech and Asymchem Partner on COVID-19 Drug FB2001 Development

CompanyDeals

GenScript ProBio Partners with ACT Therapeutics on CAR-T Cell Therapy Development

CompanyDeals

WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing

CompanyDeals

ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion

CompanyDeals

Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion

CompanyPolicy / Regulatory

Wuxi Biologics Set to Be Removed from US Restricted Trade List

Show More